INBX at a glance
Inhibrx Biosciences, Inc. (INBX, SEC CIK 2007919) filed its latest 10-K annual report on March 19, 2026, a 10-Q quarterly report on November 13, 2026, an 8-K current report on November 17, 2026 and Form 4 insider filings as recently as October 14, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 31, 2025 (FY2025), Inhibrx Biosciences, Inc. (INBX) reported revenue of $1.3 million (up 550.0% from FY2024) and a net loss of $140.1 million. Diluted EPS was -$9.04.
- As of September 30, 2026, 23 institutional investment managers tracked by SignalX reported holding Inhibrx Biosciences, Inc. (INBX) shares worth $528.9 million in 13F-HR filings.
- The most recent insider open-market purchase reported on Form 4 was by Lappe Mark on October 14, 2026 of 2,470 shares at $84.07 per share.
- In the last 90 days, INBX insiders reported 20 open-market purchases ($6.3M) and 5 open-market sales ($279K) on Form 4, a net purchase of $6.1M.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $1.3M
- +550.0% vs prior year
- Insiders · 90 days
- 20 buys · 5 sells
- Net +$6.1M
- 13F holders
- 23 funds
- $528.9M · −1 vs prior quarter
- Latest 8-K
- Nov 17, 2026
- Item 8.01
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Sep 30, 2026
Management Discussion & Analysis
- Revenue $2.0M, versus $0 in Q3 2025, entirely from Pfizer license fee revenue
- Net loss $38.7M versus $35.3M, operating loss $31.7M versus $33.8M
- R&D expense $26.0M, down 9% YoY, while G&A rose to $7.8M from $5.3M
- Cash $199.5M at September 30, 2026, with $177.8M financing inflows including $175.0M debt proceeds
- Outlook: cash sufficient for at least 12 months, but continued losses and higher clinical, manufacturing, and pre-commercialization spending expected
Risk Factors
- Newly added regulatory risk: BIOSECURE Act restricts U.S. government dealings involving designated biotechnology companies of concern
- Most materially updated manufacturing risk: FDA Form 483 observations at both ozekibart contract manufacturers threaten BLA approval
- Clinical risk: Ozekibart BLA may face a Complete Response Letter if manufacturers fail to resolve inspection findings
- Operational risk: Limited third-party manufacturers and no long-term supply agreements increase supply disruption exposure
- Market risk: Unbuilt commercialization infrastructure could impair ozekibart launch execution and reimbursement uptake
AI summary of the INBX 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 8.01: Other Events
- Updated clinical data for ozekibart, or INBRX-109, in relapsed or refractory Ewing sarcoma
- Phase 1/2 expansion study evaluates ozekibart combined with irinotecan and temozolomide
Item EX-99.1: Item EX-99.1
- Updated Phase 1/2 Ewing sarcoma data: 62.7% ORR and 86.3% DCR among 51 response-evaluable patients
- Responses included 2 complete responses and 30 partial responses, with 18 patients achieving benefit exceeding 6 months
Item 2.02: Results of Operations and Financial Condition
- Inhibrx announced financial results for the three and nine months ended September 30, 2026
- Full financial figures and management commentary are in Exhibit 99.1, the accompanying earnings release
Item EX-99.1: Item EX-99.1
- Q3 2026 net loss $38.7M, or $2.46 per share, versus $35.3M, or $2.28, in Q3 2025
- Cash $199.5M, while long-term debt rose to $276.7M from $100.6M at December 31, 2025
Item 7.01: Regulation FD Disclosure
- Updated corporate presentation posted September 28, 2026, signaling refreshed investor messaging
- Presentation likely summarizes current business updates for conferences and investor meetings
AI summaries of INBX 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for INBX
Don't miss the next INBX filing
- Alerts as it files. A push when INBX files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut INBX, by share count.
- Ask anything. An AI agent that reads every INBX filing and answers with sources.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| Lappe Mark | Buy | Oct 14, 2026 | 2,470 | $84.07 |
| Lappe Mark | Buy | Oct 14, 2026 | 2,449 | $84.07 |
| Lappe Mark | Buy | Oct 14, 2026 | 2,451 | $85.00 |
| Lappe Mark | Buy | Oct 14, 2026 | 100 | $85.76 |
| Lappe Mark | Buy | Oct 14, 2026 | 2,470 | $85.00 |
| Lappe Mark | Buy | Oct 14, 2026 | 100 | $85.76 |
| Lappe Mark | Buy | Sep 28, 2026 | 1,500 | $98.88 |
| Lappe Mark | Buy | Sep 28, 2026 | 3,000 | $101.70 |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | $1.8M | $200K | $1.3M |
| Operating Income | - | -$331.4M | -$135.0M |
| Net Income | - | $1.7B | -$140.1M |
| Op. Margin | - | -165724.0% | -10386.5% |
| Net Margin | - | 843786.0% | -10773.5% |
| Balance Sheet | |||
| Total Assets | $307.9M | $180.8M | $146.5M |
| Equity | $43.5M | $133.6M | $8.0M |
| ROE | - | 1263.3% | -1752.2% |
| Per Share | |||
| EPS | $-20.48 | $112.62 | $-9.04 |
| Cash Flow | |||
| Operating CF | - | -$194.4M | -$129.8M |
| CapEx | - | $2.6M | $31K |
Source: XBRL data in Inhibrx Biosciences, Inc. (INBX)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q3 2026Aggregate INBX share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q3 2026 | 23 | $528.9M |
| Q2 2026 | 24 | $586.8M |
| Q1 2026 | 26 | $373.0M |
| Q4 2025 | 23 | $448.1M |
| Q3 2025 | 22 | $147.5M |
| Q2 2025 | 17 | $55.4M |
| Q1 2025 | 16 | $43.8M |
| Q4 2024 | 12 | $47.5M |
- Citigroup+88.6K (+117%)
- Invesco Ltd+75.7K (+449%)
- Vanguard Capital Management LLC+44.8K (+9%)
- Morgan Stanley+12.6K (+1%)
- Northern Trust+4.4K (+4%)
- Bank of America Corp−732.9K (-87%)
- Millennium Management−136.6K (-93%)
- Goldman Sachs Group−116.5K (-34%)
- State Street Corp−74.7K (-12%)
- Viking Global Investors−15.9K (-1%)
- Citadel Advisors LLC+22.9K
- Two Sigma Investments+7.1K
Source: 13F-HR filings on SEC EDGAR (aggregated from 163 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
INBX filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 8-K | Nov 17, 2026 | - | Analysis | - |
| 8-K | Nov 13, 2026 | - | Analysis | - |
| 10-Q | Nov 13, 2026 | Sep 30, 2026 | Analysis | |
| 4 | Oct 14, 2026 | - | - | - |
| 8-K | Sep 28, 2026 | - | Analysis | - |
| 4 | Sep 28, 2026 | - | - | - |
| 4 | Sep 23, 2026 | - | - | - |
| 4 | Sep 18, 2026 | - | - | - |
| 4 | Sep 18, 2026 | - | - | - |
| 4 | Sep 18, 2026 | - | - | - |
| 4 | Sep 18, 2026 | - | - | - |
| 4 | Sep 17, 2026 | - | - | - |
| 4 | Sep 15, 2026 | - | - | - |
| 4 | Sep 10, 2026 | - | - | - |
| 8-K | Sep 8, 2026 | - | Analysis | - |
| 4 | Sep 8, 2026 | - | - | - |
| 4 | Sep 8, 2026 | - | - | - |
| 4 | Sep 8, 2026 | - | - | - |
| SC 13G | Aug 14, 2026 | - | - | |
| 8-K | Aug 13, 2026 | - | Analysis | - |
| 10-Q | Aug 13, 2026 | Jun 30, 2026 | Analysis | |
| SC 13G | Aug 3, 2026 | - | - | |
| 8-K | Jul 16, 2026 | - | Analysis | - |
| 8-K | Jun 15, 2026 | - | Analysis | - |
| 4 | Jun 4, 2026 | - | - |
Related Health Care companies
- FDMT · 4D Molecular Therapeutics, Inc.Biological Products, (No Diagnostic Substances)
- ADPT · Adaptive Biotechnologies CorpBiological Products, (No Diagnostic Substances)
- ADMA · ADMA BIOLOGICS, INC.Biological Products, (No Diagnostic Substances)
- ALEC · Alector, Inc.Biological Products, (No Diagnostic Substances)
- ALLO · Allogene Therapeutics, Inc.Biological Products, (No Diagnostic Substances)
- AMGN · AmgenBiological Products, (No Diagnostic Substances)
- AVXL · ANAVEX LIFE SCIENCES CORP.Biological Products, (No Diagnostic Substances)
- APGE · Apogee Therapeutics, Inc.Biological Products, (No Diagnostic Substances)
INBX SEC filings: frequently asked questions
Are INBX insiders buying or selling?
In the last 90 days, Inhibrx Biosciences, Inc. (INBX) officers, directors and 10% owners reported 20 open-market purchases worth $6.3 million by 3 insiders and 5 open-market sales worth $279,010 by 1 insider on Form 4, a net purchase of $6.1 million. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.
Which institutions hold INBX stock?
As of September 30, 2026, the largest Inhibrx Biosciences, Inc. (INBX) holders among the 13F filers tracked by SignalX were Morgan Stanley ($132.2 million), Viking Global Investors ($110.9 million), BlackRock ($82.3 million), State Street Corp ($56.6 million), Vanguard Capital Management LLC ($53.8 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What was INBX's revenue in fiscal year 2025?
For the fiscal year ended December 31, 2025 (FY2025), Inhibrx Biosciences, Inc. (INBX) reported revenue of $1.3 million (up 550.0% from FY2024) and a net loss of $140.1 million. Diluted EPS was -$9.04. The figures come from the XBRL data in the 10-K.
What did INBX report in its latest 8-K?
Inhibrx Biosciences, Inc. (INBX) filed an 8-K on November 17, 2026 reporting Item 8.01 (Other Events). Updated clinical data for ozekibart, or INBRX-109, in relapsed or refractory Ewing sarcoma.
What are the latest INBX SEC filings?
Inhibrx Biosciences, Inc. (INBX) filed its latest 10-K annual report on March 19, 2026, a 10-Q quarterly report on November 13, 2026, an 8-K current report on November 17, 2026 and a Form 4 insider filing on October 14, 2026.
What is INBX's SEC CIK number?
Inhibrx Biosciences, Inc. (INBX)'s SEC Central Index Key (CIK) is 2007919. EDGAR lists every INBX filing under that number.
Ask anything about INBX
The research agent reads INBX's filings, financials, insider trades and 13F holders, then answers with sources.